AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap

ADD Lonsamhet Vit

The share

Chart Bar

Financial reports and presentations



Corporate governance

  • Positive profitability trend driven by Medtech

    During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement measures.

    comments by the ceo
    Fredrik 240423 V2

Listen to our latest presentation


AddLife creates value

The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.

AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.

ADD Lonsamhet Vit

AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.

ADD Ansvar Vit

AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.

ADD Engagemang Vit

Target fulfilment 2023

Earnings growth



Contact us!

The investor pages contain all published financial information to facilitate investment decisions.

We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.


IR- and press contacts

Fredrik Dalborg (2)

Fredrik Dalborg


Christina Rubenhag

Christina Rubenhag